| Patient | Julius Caesar |
|---|---|
| Date of birth | 1972-07-12 |
| Identifiers | MRN HR-AC001-SYN; SSN (made up) 000-01-6022 |
| Document date | 2026-08-18 |
| Author | Lucius Fairbanks-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week follow-up after recurrent spells of collapse; test results and neurology consultation today. [S]
Julius Caesar returns two weeks after his first visit. He saw Dr. Lindqvist-Adeyemi of neurology this morning. He has had no further spell, though he woke once from a vivid, frightening dream, confused for a minute or two, which happens every few weeks. The EEG showed intermittent left temporal sharp waves. The MRI showed no new stroke but an old small infarct in the left posterior temporal lobe and moderate small-vessel white matter changes, with no tumor, vascular malformation, or cyst. CT angiography showed a small calcified plaque at the left carotid bifurcation, under 30 percent. The echocardiogram showed mild left ventricular thickening, no clot, and no shunt. The 14-day monitor showed sinus rhythm throughout; the one event he marked, light-headedness on standing up quickly, was in sinus rhythm. He has taken lisinopril every morning without cough or dizziness but did not keep the home blood pressure log. He has not driven, has showered rather than bathed, and has not ridden. He wants to know what the spells are and when he can drive again. [S]
| Element | Detail |
|---|---|
| Spells | None since the first visit; one confused awakening from a vivid dream |
| Tests | EEG left temporal sharp waves; MRI chronic left temporal cortical infarct, no acute infarct; CTA carotid plaque under 30 percent; echo no source of embolism; 14-day monitor sinus rhythm |
| Medicines | Lisinopril 10 mg daily; no cough or dizziness |
| Home blood pressure | Log not kept |
| Safety | Not driving, swimming, or riding |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Cardiovascular | Negative | No chest pain or palpitations; brief light-headedness on standing quickly |
| Neurological | Positive | One confused awakening from a vivid dream; no weakness, numbness, speech, or vision change; occasional mild headaches |
| Psychiatric | Negative | Impatient but not low in mood |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-08-04 | active | S |
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | 500 mg twice daily, morning and evening | Oral route | 2026-08-18 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime | Oral route | 2026-08-18 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | One tablet by mouth daily with food | Oral route | 2026-08-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-18 | Body height | 182 | cm | S |
| 2026-08-18 | Body weight | 75.8 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 140 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 68 | /min | S |
| 2026-08-18 | Respiratory rate | 14 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-18 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; alert and composed |
| Cardiovascular | Regular rhythm; no carotid bruit; blood pressure 140/88 mmHg |
| Neurological | Normal speech, naming, and repetition; visual fields full to confrontation; no pronator drift; normal strength, sensation, coordination, and gait |
| Mouth | Tongue laceration healed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found. |
| Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | I10 | S — Synthetic vascular risk factor; no blood pressure from his lifetime is known. |
| Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | E78.5 | S — Synthetic vascular risk factor; no lipid value from his lifetime is known. |
| Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | G40.209 | S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had. |
| Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | I69.398 | S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 140/88 mmHg on lisinopril 10 mg; above target |
| Self-management | Home blood pressure monitoring | Daily while treatment is adjusted | Deferred | Missed: he did not keep the home log asked for at intake during a busy fortnight. No harm judging by today's office reading (down from 152/94 to 140/88 mmHg) and normal potassium and creatinine. Corrective action: a memory cuff that stores readings, set up in the office today, and a member of his staff to remind him; readings reviewed at the next visit |
| Laboratory | Potassium and creatinine after starting an ACE inhibitor | One to two weeks after starting or changing the dose | Completed today | Potassium 4.5 mmol/L; creatinine 1.02 mg/dL (0.98 at baseline); eGFR 86 |
| Imaging | 12-lead ECG | At baseline | Up to date | Sinus rhythm, left ventricular hypertrophy by voltage, normal intervals (intake) |
| Imaging | Ambulatory rhythm monitoring for atrial fibrillation | At least 30 days within six months of the event | Ordered | 14-day patch: sinus rhythm throughout. A second monitor for four more weeks fitted today |
| Imaging | Brain MRI and EEG | At diagnosis | Completed today | MRI: chronic left posterior temporal cortical infarct, moderate white matter changes, no acute infarct or other lesion. EEG: left temporal sharp waves |
| Imaging | Vascular imaging and echocardiogram | At diagnosis of an ischemic infarct | Completed today | CTA: left carotid plaque under 30 percent, no intracranial stenosis. Echo: no thrombus or shunt, ejection fraction 60 percent |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting | Due | Atorvastatin 80 mg started today; panel at the ten-week visit |
| Laboratory | Diabetes screen | At baseline | Up to date | HbA1c 5.6 percent at intake |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin 81 mg started today; dual antiplatelet therapy is for a recent minor stroke or high-risk TIA, not an old infarct |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | Levetiracetam 500 mg twice daily started today, with written teaching |
| Survey | Depression screen (PHQ-9) | At the first visit after the event, then periodically | Up to date | 3 at intake; repeat at four weeks on levetiracetam |
| Survey | Cognitive screen (MoCA) | In the first year after a stroke | Due | At the next visit |
| Examination | Sleep apnea evaluation | Consider after any stroke | Ordered | STOP-Bang 3; home sleep apnea test ordered |
| Examination | Fall risk | Every visit | Completed today | No fall apart from the seizure; seizure precautions cover the risk |
| Examination | Weight and BMI | Every visit | Completed today | 75.8 kg; BMI 22.9 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Never smoker; little alcohol; Mediterranean-style diet with less salt agreed; walking daily |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; no swimming or riding alone; showers only; seizure action plan given to his staff |
| Referral | Neurology consultation | At presentation | Completed today | Seen today; diagnosis and treatment agreed |
Goal progress:
Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology (2017); ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology (2017); ILAE official report: a practical clinical definition of epilepsy (2014); Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope (2017); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026)
Follow-up: Four-week chronic-care visit with the monitor results, home blood pressure readings, PHQ-9, and MoCA. Next scheduled visit 2026-09-15: four-week review of levetiracetam, blood pressure, the second rhythm monitor, mood, and cognition. [S]